MX2015008502A - Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas. - Google Patents

Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas.

Info

Publication number
MX2015008502A
MX2015008502A MX2015008502A MX2015008502A MX2015008502A MX 2015008502 A MX2015008502 A MX 2015008502A MX 2015008502 A MX2015008502 A MX 2015008502A MX 2015008502 A MX2015008502 A MX 2015008502A MX 2015008502 A MX2015008502 A MX 2015008502A
Authority
MX
Mexico
Prior art keywords
propyl
diisobutylamino
piperazin
imidazol
benzo
Prior art date
Application number
MX2015008502A
Other languages
English (en)
Other versions
MX363367B (es
Inventor
Stéphane Burlet
Cécilia Estrella
Mathieu Barrier
Patricia Melnyk
Nicolas Sergeant
Luc Buee
Philippe Verwaerde
Original Assignee
Alzprotect
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzprotect filed Critical Alzprotect
Publication of MX2015008502A publication Critical patent/MX2015008502A/es
Publication of MX363367B publication Critical patent/MX363367B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con las sales sulfato de N-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il)propil)-1H-benz o [d]imidazol-2-amina y los solvatos farmacéuticamente aceptable de las mismas, la preparación de las mismas, con las composiciones farmacéuticas que las contienen y el uso de las mismas en el tratamiento y/o la prevención de enfermedades de neurodegenerativas.
MX2015008502A 2012-12-27 2013-12-27 Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas. MX363367B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306690 2012-12-27
PCT/EP2013/078068 WO2014102339A1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Publications (2)

Publication Number Publication Date
MX2015008502A true MX2015008502A (es) 2015-12-16
MX363367B MX363367B (es) 2019-03-20

Family

ID=47501005

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008502A MX363367B (es) 2012-12-27 2013-12-27 Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas.

Country Status (24)

Country Link
US (3) US9562018B2 (es)
EP (1) EP2938597B1 (es)
JP (1) JP6384923B2 (es)
KR (1) KR102115060B1 (es)
CN (1) CN105008333B (es)
AU (2) AU2013369288B2 (es)
BR (1) BR112015015474B1 (es)
CA (1) CA2895285C (es)
DK (1) DK2938597T3 (es)
ES (1) ES2605494T3 (es)
HK (1) HK1215582A1 (es)
HR (1) HRP20161612T2 (es)
HU (1) HUE030930T2 (es)
IL (1) IL239450B (es)
LT (1) LT2938597T (es)
MX (1) MX363367B (es)
NZ (1) NZ708959A (es)
PL (1) PL2938597T3 (es)
PT (1) PT2938597T (es)
RS (1) RS55511B1 (es)
RU (1) RU2655454C2 (es)
SI (1) SI2938597T1 (es)
WO (1) WO2014102339A1 (es)
ZA (1) ZA201504521B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6384923B2 (ja) 2012-12-27 2018-09-05 アルツプロテクト Ｎ−（３−（４−（３−（ジイソブチルアミノ）プロピル）ピペラジン−１−イル）プロピル）−１Ｈ−ベンゾ［ｄ］イミダゾール−２−アミンの硫酸塩、その製造、及びその使用
WO2016146655A1 (en) 2015-03-16 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
EP4222144A1 (en) 2020-10-01 2023-08-09 Alzprotect Succinate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
EP4225306A1 (en) 2020-10-07 2023-08-16 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders
WO2023117990A1 (en) 2021-12-20 2023-06-29 Alzprotect USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[d]IMIDAZOL-2-AMINE SUCCINATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS
WO2023180537A1 (en) 2022-03-25 2023-09-28 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
WO1998056423A1 (fr) * 1997-06-12 1998-12-17 Transgene S.A. Nouveaux complexes lipidiques pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
EP1117663A2 (en) 1998-09-30 2001-07-25 Neurogen Corporation 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
WO2004056800A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
EP1809288B1 (en) 2004-11-10 2011-09-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases
JP6384923B2 (ja) * 2012-12-27 2018-09-05 アルツプロテクト Ｎ−（３−（４−（３−（ジイソブチルアミノ）プロピル）ピペラジン−１−イル）プロピル）−１Ｈ−ベンゾ［ｄ］イミダゾール−２−アミンの硫酸塩、その製造、及びその使用

Also Published As

Publication number Publication date
US10772884B2 (en) 2020-09-15
HRP20161612T1 (hr) 2017-01-27
US20170151235A1 (en) 2017-06-01
JP6384923B2 (ja) 2018-09-05
ZA201504521B (en) 2016-11-30
HRP20161612T2 (hr) 2017-02-24
AU2013369288A1 (en) 2015-07-02
AU2013369288A8 (en) 2015-07-16
WO2014102339A1 (en) 2014-07-03
DK2938597T3 (en) 2017-01-09
US20190381036A1 (en) 2019-12-19
JP2016503813A (ja) 2016-02-08
IL239450A0 (en) 2015-07-30
RU2015130671A (ru) 2017-01-30
US10537569B2 (en) 2020-01-21
BR112015015474B1 (pt) 2022-04-19
RS55511B1 (sr) 2017-05-31
KR102115060B1 (ko) 2020-05-25
PL2938597T3 (pl) 2017-03-31
PT2938597T (pt) 2016-12-09
LT2938597T (lt) 2017-01-25
CN105008333B (zh) 2018-02-09
AU2013369288B2 (en) 2018-02-22
BR112015015474A2 (es) 2017-08-15
US9562018B2 (en) 2017-02-07
HK1215582A1 (zh) 2016-09-02
CA2895285C (en) 2021-03-30
IL239450B (en) 2018-06-28
AU2018202218B2 (en) 2019-02-21
MX363367B (es) 2019-03-20
CN105008333A (zh) 2015-10-28
CA2895285A1 (en) 2014-07-03
NZ708959A (en) 2019-11-29
RU2655454C2 (ru) 2018-05-29
US20160108003A1 (en) 2016-04-21
AU2018202218A1 (en) 2018-04-26
HUE030930T2 (hu) 2017-06-28
KR20150105313A (ko) 2015-09-16
EP2938597A1 (en) 2015-11-04
EP2938597B1 (en) 2016-10-26
ES2605494T3 (es) 2017-03-14
SI2938597T1 (sl) 2017-03-31

Similar Documents

Publication Publication Date Title
NZ708959A (en) Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
IN2015DN01156A (es)
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
WO2014028591A3 (en) N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2013004307A (es) Derivados de arilamida como bloqueadores de ttx-s.
MY175854A (en) Novel quinolone derivatives
MX2013007957A (es) 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2).
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
MX369803B (es) Derivados de acilaminopirimidina para el tratamiento de infecciones viricas y otras enfermedades.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
PH12015502365B1 (en) Bace1 inhibitors
MX366308B (es) Derivados de amida como bloqueadores de ttx-s.
MX2013014194A (es) 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2).
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
UA117154C2 (uk) Антагоністи s1p3
AU2013260056A8 (en) Compounds with TRPV4 activity, compositions and associated methods thereof
IN2015DN02109A (es)
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2014002141A (es) Carboxamidas de n-(5-cicloalquil - o 5-heterociclil-)-piridin-3-il o.